Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.56

T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant (2012) 1.42

Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer (2008) 1.40

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer (2010) 1.09

Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med (2010) 0.99

Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2009) 0.95

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer (2008) 0.94

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leuk Lymphoma (2008) 0.91

Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer (2010) 0.84

Clinical applications of BCR-ABL molecular testing in acute leukemia. J Mol Diagn (2003) 0.83

Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma (2010) 0.83

Autologous Hematopoietic Stem Cell Transplantation for High-risk Acute Lymphoblastic Leukemia: non-Randomized Study with a maximum Follow-up of more than 22 Years. Mediterr J Hematol Infect Dis (2014) 0.79

Autologous stem cell transplantation in hematological malignancies. Springer Semin Immunopathol (2004) 0.79

Cellular therapies in acute lymphoblastic leukemia. Hematol Oncol Clin North Am (2011) 0.78

Cellular therapies in acute lymphoblastic leukemia. Curr Opin Mol Ther (2009) 0.77

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL). Bone Marrow Transplant (2015) 0.75

Imaging findings in recurrent extramedullary leukaemias. Cancer Imaging (2013) 0.75

Outcomes of a modified CALGB 19802 regimen in adult acute lymphoblastic leukemia. J Korean Med Sci (2008) 0.75

Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease: Analysis from a Single Center of China. Chin Med J (Engl) (2015) 0.75

Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study. Sci Rep (2016) 0.75

Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia. Clin Case Rep (2016) 0.75

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood (1995) 16.81

The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2005) 7.03

Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med (2001) 5.31

The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 5.24

Acute promyelocytic leukemia. N Engl J Med (1993) 4.63

All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood (1990) 4.36

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet (1998) 3.62

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood (2000) 3.01

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1999) 2.98

Treatment of acute hypoxemic nonhypercapnic respiratory insufficiency with continuous positive airway pressure delivered by a face mask: A randomized controlled trial. JAMA (2000) 2.91

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol (1998) 2.74

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.54

Adult T-biphenotypic acute leukaemia: clinical and biological features and outcome. Br J Haematol (2003) 2.36

A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA (2000) 2.34

Noninvasive versus conventional mechanical ventilation. An epidemiologic survey. Am J Respir Crit Care Med (2001) 2.31

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol (2000) 2.30

Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma. Ann Oncol (2003) 2.28

The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene (1995) 2.23

Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23

Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood (1992) 2.11

Induction of the PML protein by interferons in normal and APL cells. Leukemia (1995) 2.05

Is there a limit to the normality of blood products? Hematol J (2000) 2.00

Cytokine-mediated expansion of 5-FU-resistant peripheral blood stem cells. Exp Hematol (1995) 1.99

What's new in blood progenitor cell autotransplants? Bone Marrow Transplant (1994) 1.98

Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med (1995) 1.94

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med (1999) 1.91

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1998) 1.90

Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature (1990) 1.87

Therapy-related acute promyelocytic leukemia. J Clin Oncol (2003) 1.82

PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 1.82

Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia (2004) 1.81

Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells. Blood (1993) 1.78

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Leukemia (2006) 1.77

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77

Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol (1997) 1.77

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia (2006) 1.76

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (1997) 1.71

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood (2001) 1.67

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood (1998) 1.65

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 1.63

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia (2007) 1.63

Prevalence, etiologies and outcome of the acute respiratory distress syndrome among hypoxemic ventilated patients. SRLF Collaborative Group on Mechanical Ventilation. Société de Réanimation de Langue Française. Intensive Care Med (1999) 1.60

Diagnostic value of dominant T-cell clones in peripheral blood in 363 patients presenting consecutively with a clinical suspicion of cutaneous lymphoma. Blood (2000) 1.59

Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells. Eur J Immunol (1978) 1.58

PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors. Proc Natl Acad Sci U S A (1994) 1.57

Neutrophilic dermatoses during granulocytopenia. Arch Dermatol (1995) 1.56

Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol (2000) 1.56

Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia (2000) 1.55

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol (1995) 1.52

A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest (1990) 1.51

High prevalence of human Parechovirus (HPeV) genotypes in the Amsterdam region and identification of specific HPeV variants by direct genotyping of stool samples. J Clin Microbiol (2008) 1.51

Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leuk Res (1997) 1.50

The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood (1998) 1.49

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48

Acquired IgG antibody occurring in a thrombasthenic patient: its effect on human platelet function. Blood (1978) 1.47

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood (1996) 1.47

New insights in biology and current therapeutic options for patients with chronic myelogenous leukemia. Haematologica (1997) 1.47

Antisense oligomers in chronic myeloid leukaemia. Lancet (1993) 1.45

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44

Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia. Leukemia (1998) 1.44

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group. Leukemia (2005) 1.44

Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood (1998) 1.42

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia (2012) 1.42

Phase I trials in cancer treatment. The maximum tolerated dose: a barbarian guideline. Hematol J (2000) 1.41

A human minor histocompatibility antigen which appears to segregate with the major histocompatibility complex. Transplantation (1994) 1.39

A novel immunodeficient mouse model--RAG2 x common cytokine receptor gamma chain double mutants--requiring exogenous cytokine administration for human hematopoietic stem cell engraftment. J Interferon Cytokine Res (1999) 1.38

Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (1994) 1.38

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37

Absence of graft-versus-leukemia (GVL) effect by leucocytes transfused: a prospective randomized trial in acute myeloid leukemia (AML) patients. Br J Haematol (1991) 1.37

Allogeneic bone marrow transplantation versus chemotherapy in first-remission acute myeloid leukemia. J Clin Oncol (1989) 1.36

Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia (1997) 1.36

A molecular defect in thrombasthenic platelets. J Clin Invest (1975) 1.36

Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). Blood (1995) 1.36

Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol (2001) 1.36

Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol (2001) 1.35

Impaired antibody affinity maturation process characterizes a subset of patients with common variable immunodeficiency. J Immunol (2000) 1.35

A haplotype study of HLA complex with special reference to the HLA-DR series and to Bf. C2 and glyoxalase I polymorphisms. Tissue Antigens (1978) 1.35

The association of the HL-A antigens with diseases. Clin Immunol Immunopathol (1974) 1.34

Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol (2000) 1.34

Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol (1997) 1.33

Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res (1997) 1.32

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol (1998) 1.31

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31

Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol (1990) 1.30

All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood (1990) 1.30

Allogeneic bone marrow transplantation for low-grade lymphoma. Blood (1998) 1.29